Compare · DXR vs MDLN
DXR vs MDLN
Side-by-side comparison of Daxor Corporation (DXR) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXR and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $51.52B, about 1055.6x DXR ($48.8M).
- MDLN has been more active in the news (13 items in the past 4 weeks vs 1 for DXR).
- MDLN has more recent analyst coverage (25 ratings vs 0 for DXR).
- Company
- Daxor Corporation
- Medline Inc.
- Price
- -
- -
- Market cap
- $48.8M
- $51.52B
- 1M return
- -
- +8.89%
- 1Y return
- -
- -3.93%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 1
- 13
- Recent ratings
- 0
- 25
Daxor Corporation
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Latest DXR
- Amendment: SEC Form N-CEN/A filed by Daxor Corporation
- Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
- Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026
- Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026
- Amendment: SEC Form 40-8F-2/A filed by Daxor Corporation
- Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
- Amendment: SEC Form N-CEN/A filed by Daxor Corporation
- Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
- Chief Medical Officer Jefferies John was granted 2,451 units of Daxor Common Stock, increasing direct ownership by 10% to 26,008 units (SEC Form 4)
- Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Latest MDLN
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock
- SEC Form S-1 filed by Medline Inc.
- SEC Form SCHEDULE 13G filed by Medline Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits